| Status: AWMSG assessment in progress | |
Off-label neoadjuvant treatment for patients with resectable macroscopic stage III melanoma with ≥1 pathologically proven lymph node metastasis and up to 3 in-transit metastases. |
|
Medicine details |
|
| Medicine name | nivolumab (Opdivo®) + ipilimumab (Yervoy®) |
| Formulation | intravenous infusion |
| Reference number | OW35 |
| Indication | As above |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | One Wales |
| Status | AWMSG assessment in progress |
| Scrutiny Panel meeting date | 03/11/2025 |
| OWMAG meeting date | 09/02/2026 |
| AWMSG meeting date | 11/03/2026 |